News
-
23.06.2009
Salvacyl®, developed by Debiopharm, is launched in two European countries - a new therapeutic avenue for the treatment of sexual deviations - -
18.06.2009
Debiopharm Group and Moffitt Cancer Center sign development and commercialisation agreement for small molecule Debio 0928 in early preclinical development for treatment of solid tumours - A novel drug with potential to block cancer cell proliferation
Home
| Partnering |
Why partner with usFor biotechnology and pharmaceutical partners, for academic and research organisations we offer flexible deal terms to:
In addition to this, we cater to biotechnology and pharmaceutical partners by validating your technology to further attract commercial partners and by financing early-stage projects through equity participation or acquisitions. We can also mitigate the risk and help you release your human and financial resources. Particularly for academic and research organisations, our commercial orientated development is an advantage.
For licensing contacts, please use this form.
|



